Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Background: Traditional systemic immunosuppressants and advanced therapies improve signs and symptoms of moderate-to-severe atopic dermatitis (AD). However, data are limited in severe and/or difficult-to-treat AD.
doi: 10.1016/j.eclinm.2023.102002. Affiliations Affiliations 1 George Washington University School of Medicine and Health Sciences, Washington, DC, USA. 2 Northwestern University Feinberg School of Medicine, Chicago, IL, USA. 3 Department of Dermatology, Oregon Health & Science University, Portland, OR, USA. 4 AOBiome Therapeutics, Inc., Cambridge, MA, USA. 5 Biorasi, LLC, Aventura, FL, USA. 6 Veristat, LLC, Southborough, MA, USA.
Importance: Safe and effective long-term treatments for adolescents with moderate to severe atopic dermatitis (AD) are limited. Objective: To evaluate the efficacy and safety of interleukin-13-targeted treatment with tralokinumab monotherapy in adolescents with AD.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
